Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIAN-SHAN7: DZD6008 Combination Therapy in Advanced NSCLC With EGFR Mutation
NCT07070440Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of DZD6008 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 1 year and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
DZD6008
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07070440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070440.